- Home
- CTRA vs RPRX Comparison
CTRA vs RPRX Comparison
Compare CTRA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTRA | RPRX |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 16.2B |
| IPO Year | 1990 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTRA | RPRX |
|---|---|---|
| Price | $27.49 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 3 |
| Target Price | $32.75 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 6.8M | 4.3M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.21% | 2.21% |
| EPS Growth | ★ 31.20 | N/A |
| EPS | ★ 2.17 | 1.75 |
| Revenue | ★ $6,666,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $47.52 | $37.13 |
| Revenue Next Year | $5.65 | $1.48 |
| P/E Ratio | ★ $12.64 | $22.68 |
| Revenue Growth | ★ 25.92 | 3.70 |
| 52 Week Low | $22.33 | $24.05 |
| 52 Week High | $29.95 | $41.24 |
Technical Indicators
Market Signals| Indicator | CTRA | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.96 | 57.50 |
| Support Level | $26.39 | $39.24 |
| Resistance Level | $27.24 | $40.50 |
| Average True Range (ATR) | 0.61 | 0.91 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 77.50 | 76.02 |
Price Performance
Historical ComparisonAbout CTRA Coterra Energy Inc.
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.